- Home
- PVH vs LEGN Comparison
PVH vs LEGN Comparison
Compare PVH & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVH
- LEGN
- Stock Information
- Founded
- PVH 1881
- LEGN 2014
- Country
- PVH United States
- LEGN United States
- Employees
- PVH N/A
- LEGN N/A
- Industry
- PVH Apparel
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- PVH Consumer Discretionary
- LEGN Health Care
- Exchange
- PVH Nasdaq
- LEGN Nasdaq
- Market Cap
- PVH 6.1B
- LEGN 5.4B
- IPO Year
- PVH N/A
- LEGN 2020
- Fundamental
- Price
- PVH $83.76
- LEGN $28.95
- Analyst Decision
- PVH Buy
- LEGN Strong Buy
- Analyst Count
- PVH 15
- LEGN 12
- Target Price
- PVH $104.93
- LEGN $77.09
- AVG Volume (30 Days)
- PVH 1.3M
- LEGN 1.9M
- Earning Date
- PVH 06-04-2025
- LEGN 05-13-2025
- Dividend Yield
- PVH 0.18%
- LEGN N/A
- EPS Growth
- PVH N/A
- LEGN N/A
- EPS
- PVH 10.56
- LEGN N/A
- Revenue
- PVH $8,652,900,000.00
- LEGN $728,303,000.00
- Revenue This Year
- PVH $0.94
- LEGN $64.21
- Revenue Next Year
- PVH $2.10
- LEGN $53.69
- P/E Ratio
- PVH $7.93
- LEGN N/A
- Revenue Growth
- PVH N/A
- LEGN 112.46
- 52 Week Low
- PVH $59.28
- LEGN $27.34
- 52 Week High
- PVH $124.68
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- PVH 58.41
- LEGN 41.56
- Support Level
- PVH $79.60
- LEGN $28.13
- Resistance Level
- PVH $87.90
- LEGN $29.31
- Average True Range (ATR)
- PVH 2.57
- LEGN 1.63
- MACD
- PVH -0.04
- LEGN 0.03
- Stochastic Oscillator
- PVH 56.06
- LEGN 27.01
About PVH PVH Corp.
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites and about 1,500 stores, licenses its brands to third parties, and distributes its merchandise through department stores and other wholesale accounts. The firm traces its history to 1881 and is based in New York City.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.